Spots Global Cancer Trial Database for her2 positive breast cancer
Every month we try and update this database with for her2 positive breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cardiac Safety Study in Patients With HER2 + Breast Cancer | NCT01904903 | HER2 Positive B... Left Ventricula... | Trastuzumab Pertuzumab Ado Trastuzumab... | 18 Years - 120 Years | Medstar Health Research Institute | |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Pre Operative Trastuzumab in Operable Breast Cancer | NCT01785420 | Carcinoma Breas... HER2 Positive B... | Trastuzumab Placebo | 18 Years - 80 Years | Tata Memorial Hospital | |
| A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer | NCT00951665 | Metastatic Brea... | paclitaxel pertuzumab [Per... trastuzumab emt... paclitaxel trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer | NCT02476539 | HER2 Positive B... | Hemay022 | 18 Years - 65 Years | Ganzhou Hemay Pharmaceutical Co., Ltd | |
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects | NCT03242239 | Healthy | ALT02 EU-licensed Her... US-licensed Her... | 18 Years - 55 Years | Alteogen, Inc. | |
| BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab | NCT00625898 | Breast Cancer | Docetaxel Trastuzumab Carboplatin Bevacizumab 5-Fluorouracil Epirubicin Cyclophosphamid... | 18 Years - | NSABP Foundation Inc | |
| Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients | NCT00270894 | Breast Neoplasm | epirubicin cyclophosphamid... docetaxel trastuzumab | 18 Years - | Accelerated Community Oncology Research Network | |
| Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | NCT00258960 | Breast Cancer | Liposomal Doxor... Cyclophosphamid... Trastuzumab | 18 Years - 75 Years | Spanish Breast Cancer Research Group | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib | NCT05252988 | Early-stage Bre... HER2 Positive B... Hormone Recepto... | Neratinib Loperamide Colesevelam | 18 Years - | Spanish Breast Cancer Research Group | |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | NCT02125344 | Tubular Breast ... Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... HER2 Positive B... Inflammatory Br... | non-pegylated l... Carboplatin Paclitaxel Epirubicin Cyclophosphamid... Pertuzumab Trastuzumab Ferric carboxym... | 18 Years - | German Breast Group | |
| Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. | NCT03947242 | HER2 Positive B... | Pyrotinib and T... | 18 Years - 70 Years | Henan Cancer Hospital | |
| A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | NCT02362958 | HER2 Positive B... | lapatinib and c... | 18 Years - 65 Years | Sun Yat-sen University | |
| A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer | NCT02025192 | HER2 Positive M... | Tucatinib Capecitabine Trastuzumab | 18 Years - | Seagen Inc. | |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | NCT05132582 | HER2 Positive B... | Tucatinib Trastuzumab Pertuzumab Combination pro... Placebo | 18 Years - | Seagen Inc. | |
| A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | NCT00679341 | Breast Cancer | Trastuzumab emt... Trastuzumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer | NCT01840306 | Breast Cancer HER2 Positive B... HER2 Negative B... | Biomarker Analy... | 18 Years - | Cancer Trials Ireland | |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | NCT02213744 | Breast Cancer HER2 Positive B... | MM-302 Gemcitabine Capecitabine Vinorelbine Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects | NCT03242239 | Healthy | ALT02 EU-licensed Her... US-licensed Her... | 18 Years - 55 Years | Alteogen, Inc. | |
| A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer | NCT02149524 | HER2 Positive E... | Herceptin (tras... SB3 (proposed t... | 18 Years - 65 Years | Samsung Bioepis Co., Ltd. | |
| Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. | NCT03735966 | HER2 Positive B... | Pyrotinib plus ... | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi | |
| Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | NCT01306942 | Metastatic Brea... | Dasatinib Trastuzumab Paclitaxel | 18 Years - | Spanish Breast Cancer Research Group | |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | NCT00817362 | Breast Cancer HER2 Positive B... Metastatic Brea... Cancer of the B... | IPI-504 Trastuzumab | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer | NCT02614794 | HER2 Positive B... | tucatinib capecitabine trastuzumab placebo | 18 Years - | Seagen Inc. | |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Cardiac Safety Study in Patients With HER2 + Breast Cancer | NCT01904903 | HER2 Positive B... Left Ventricula... | Trastuzumab Pertuzumab Ado Trastuzumab... | 18 Years - 120 Years | Medstar Health Research Institute | |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer | NCT04539938 | HER2 Positive B... | tucatinib trastuzumab der... | 18 Years - | Seagen Inc. | |
| Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer | NCT01340430 | HER-2 Positive ... | Trastuzumab | 18 Years - | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi | |
| A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | NCT02362958 | HER2 Positive B... | lapatinib and c... | 18 Years - 65 Years | Sun Yat-sen University | |
| IRS Proteins and Trastuzumab Resistance | NCT00657345 | Breast Cancer | 18 Years - 70 Years | University of Massachusetts, Worcester | ||
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | NCT02125344 | Tubular Breast ... Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... HER2 Positive B... Inflammatory Br... | non-pegylated l... Carboplatin Paclitaxel Epirubicin Cyclophosphamid... Pertuzumab Trastuzumab Ferric carboxym... | 18 Years - | German Breast Group | |
| Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | NCT01306942 | Metastatic Brea... | Dasatinib Trastuzumab Paclitaxel | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | NCT00486668 | Invasive Breast... | doxorubicin cyclophosphamid... paclitaxel trastuzumab lapatinib | 18 Years - | NSABP Foundation Inc | |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer | NCT04539938 | HER2 Positive B... | tucatinib trastuzumab der... | 18 Years - | Seagen Inc. | |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | NCT00817362 | Breast Cancer HER2 Positive B... Metastatic Brea... Cancer of the B... | IPI-504 Trastuzumab | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging | NCT02993198 | HER2 Positive B... Cardiovascular ... | Carvedilol | 18 Years - | Northwestern University | |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) | NCT02682693 | Breast Cancer F... Tubular Breast ... Mucinous Breast... Invasive Ductal... HER2 Positive B... Inflammatory Br... Tubular Breast ... | Denosumab nab-Paclitaxel Epirubicin Cyclophosphamid... Carboplatin Trastuzumab Pertuzumab | 18 Years - 75 Years | German Breast Group | |
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects | NCT03242239 | Healthy | ALT02 EU-licensed Her... US-licensed Her... | 18 Years - 55 Years | Alteogen, Inc. | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi | |
| Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer | NCT02476539 | HER2 Positive B... | Hemay022 | 18 Years - 65 Years | Ganzhou Hemay Pharmaceutical Co., Ltd | |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | NCT02213744 | Breast Cancer HER2 Positive B... | MM-302 Gemcitabine Capecitabine Vinorelbine Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) | NCT02705859 | HER2 Positive B... | Copanlisib Trastuzumab | 18 Years - | Cancer Trials Ireland | |
| Pre Operative Trastuzumab in Operable Breast Cancer | NCT01785420 | Carcinoma Breas... HER2 Positive B... | Trastuzumab Placebo | 18 Years - 80 Years | Tata Memorial Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
